Rimonabant
Rimonabant (pronounced ri-MO-na-bant) is a type of pharmaceutical drug that was first approved in Europe in 2006 but was later withdrawn worldwide in 2008 due to serious psychiatric side effects. It was never approved in the United States.
Etymology
The name "Rimonabant" is derived from the name of the company that developed the drug, Sanofi-Aventis, and the word "antagonist," which refers to the drug's mechanism of action.
Pharmacology
Rimonabant is an anorectic anti-obesity drug. It is a selective CB1 receptor antagonist that inhibits the action of endocannabinoids, which are chemicals in the body that bind to these receptors. By blocking the CB1 receptors, Rimonabant reduces appetite and food intake, leading to weight loss.
Uses
Rimonabant was used to treat obesity in people who were also at risk for other health conditions, such as diabetes or heart disease. It was also studied for its potential use in smoking cessation therapy, due to its effects on the reward system of the brain.
Side Effects
The use of Rimonabant was associated with a number of psychiatric side effects, including depression, anxiety, and suicidal ideation. These side effects led to the withdrawal of the drug from the market.
See Also
External links
- Medical encyclopedia article on Rimonabant
- Wikipedia's article - Rimonabant
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski